Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function

NCT01508806 · Completed

Last updated 2026-05-28

This clinical trial tested the safety and tolerability of the medication liraglutide in adults with type 2 diabetes who have either normal or impaired kidney function.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 30 people

Who can join Ages 18–75 · all sexes

Timeline Started 2005-08 · est. completion 2006-03

Where 1 site · Australia

What this study is testing ClinicalTrials.gov NCT01508806 ↗

Description as written by the study sponsor.

This trial is conducted in Oceania. The aim of this trial is to assess whether dose adjustment is required for patients with renal impairment by investigating the pharmacokinetics of liraglutide in subjects with various degrees of renal impairment.

Treatments tested

liraglutide Drug

Single dose of 0.75 mg, administered as a subcutaneous injection

Main thing measured	Area under the Curve (AUC)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01508806 ↗